HK219096A - Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides - Google Patents

Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides Download PDF

Info

Publication number
HK219096A
HK219096A HK219096A HK219096A HK219096A HK 219096 A HK219096 A HK 219096A HK 219096 A HK219096 A HK 219096A HK 219096 A HK219096 A HK 219096A HK 219096 A HK219096 A HK 219096A
Authority
HK
Hong Kong
Prior art keywords
tenidap
cholesterol
triglycerides
mammal
pharmaceutically
Prior art date
Application number
HK219096A
Other languages
German (de)
English (en)
French (fr)
Inventor
David Loose Leland
Ting Naitee
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HK219096A publication Critical patent/HK219096A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK219096A 1991-02-08 1996-12-24 Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides HK219096A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65270991A 1991-02-08 1991-02-08
US07/727,786 US5122534A (en) 1991-02-08 1991-07-10 Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides

Publications (1)

Publication Number Publication Date
HK219096A true HK219096A (en) 1997-01-03

Family

ID=27096345

Family Applications (1)

Application Number Title Priority Date Filing Date
HK219096A HK219096A (en) 1991-02-08 1996-12-24 Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides

Country Status (17)

Country Link
US (1) US5122534A (cs)
EP (1) EP0498588B1 (cs)
JP (1) JPH0558893A (cs)
KR (1) KR940011245B1 (cs)
AT (1) ATE121620T1 (cs)
AU (1) AU630580B2 (cs)
CA (1) CA2060789C (cs)
DE (1) DE69202162T2 (cs)
DK (1) DK0498588T3 (cs)
HK (1) HK219096A (cs)
HU (1) HUT62194A (cs)
IE (1) IE65596B1 (cs)
MX (1) MX9200544A (cs)
MY (1) MY106885A (cs)
NZ (1) NZ241555A (cs)
PT (1) PT100095A (cs)
TW (1) TW206153B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19513716A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Substituierte 2-Phenylindol-Derivate
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
WO1997022605A1 (en) * 1995-12-19 1997-06-26 Pfizer Inc. Stable, long acting salts of indole derivatives for the treatment of joint diseases
EP0826685A1 (en) * 1996-08-21 1998-03-04 Pfizer Inc. Stable, long acting salts of carboxamides for the treatment of joint disease
AU2002249893B2 (en) * 2001-01-02 2007-05-24 The Cleveland Clinic Foundation Myeloperoxidase, a risk indicator for cardiovascular disease
US7780950B2 (en) * 2002-01-02 2010-08-24 The Cleveland Clinic Foundation Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
US20060004088A1 (en) * 2002-10-22 2006-01-05 Oct Inc. Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
US7459286B1 (en) 2003-10-22 2008-12-02 The Cleveland Clinic Foundation Assessing the risk of a major adverse cardiac event in patients with chest pain
EP1697746B1 (en) * 2003-12-05 2012-02-22 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
WO2006020498A2 (en) 2004-08-11 2006-02-23 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
US5036099A (en) * 1987-02-02 1991-07-30 Pfizer Inc. Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide
US4861794A (en) * 1988-04-13 1989-08-29 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
US4853409A (en) * 1988-04-13 1989-08-01 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function
US5006547A (en) * 1990-03-19 1991-04-09 Pfizer Inc. Tenidap as an inhibitor of the release of elastase by neutrophils
US5008283A (en) * 1990-03-19 1991-04-16 Pfizer Inc. Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase

Also Published As

Publication number Publication date
CA2060789A1 (en) 1992-08-09
HUT62194A (en) 1993-04-28
AU1083192A (en) 1992-08-20
MX9200544A (es) 1992-08-01
DK0498588T3 (da) 1995-07-10
ATE121620T1 (de) 1995-05-15
HU9200395D0 (en) 1992-04-28
JPH0558893A (ja) 1993-03-09
AU630580B2 (en) 1992-10-29
CA2060789C (en) 1995-10-17
MY106885A (en) 1995-08-30
IE920405A1 (en) 1992-08-12
DE69202162D1 (de) 1995-06-01
DE69202162T2 (de) 1995-08-31
EP0498588A1 (en) 1992-08-12
TW206153B (cs) 1993-05-21
NZ241555A (en) 1997-02-24
KR920016094A (ko) 1992-09-24
IE65596B1 (en) 1995-11-01
PT100095A (pt) 1993-04-30
US5122534A (en) 1992-06-16
KR940011245B1 (ko) 1994-12-03
EP0498588B1 (en) 1995-04-26

Similar Documents

Publication Publication Date Title
EP0498588B1 (en) Use of tenidap to reduce total serum cholesterol, LDL cholesterol and triglycerides
RU2147875C1 (ru) Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего
EP1138329B1 (en) Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions
CA1323572C (en) Doxazosin as an anti-atherosclerosis agent
EP0337628B1 (en) 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function
US5008283A (en) Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
AU604176B2 (en) Dl-5-{2-benzyl-3,4-dihydro-2h-benzopyran-6-yl}methyl} thiazolidine-2,4-dione as an anti-atherosclerosis agent
US6264960B1 (en) Treatment of vascular events using lipid-modifying compositions
US5543411A (en) Hydroxylated metabolites and derivatives of doxazosin as anti-atherosclerosis agents
FI118414B (fi) Hypokolesteroleemisia, antiateroskleroottisia ja hypotriglyserideemisiä merkaptoasetyyliamidijohdannaisia
Ballantyne et al. 1084-176 Efficacy of ezetimibe coadministered with simvastatin versus atorvastatin in patients with hypercholesterolemia
Goldberg et al. 1084-174 Efficacy of ezetimibe-10 mg/day coadministered with multiple doses of simvastatin in patients with primary hypercholesterolemia
Nagata et al. FY-038: A novel ACAT inhibitor that inhibits cholesterol absorption and affects diet-induced atherosclerosis in mice
Jan et al. Assessment of cardiovascular outcomes by holter monitoring during LDL apheresis in hypercholesterolemic patients: results of the French Multicenter Study
Kamei et al. Effects of NB-598, a squalene epoxidase inhibitor, on the secretion of apolipoprotein B
HK1084329B (en) Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20050203